Asthma, COPD, Healthy
Conditions
Keywords
Hyperpolarized Xenon, HXe, MagniXene
Brief summary
The purpose of this clinical trial is to demonstrate hyperpolarized xenon (HXe) as a medical imaging drug (agent) for Magnetic Resonance Imaging (MRI) of the human lung ventilation.
Detailed description
HXe MRI provides a diversity of imaging techniques for interrogating pulmonary function and lung microstructure. The most mature of these techniques utilizes HXe spin-density MRI to depict regional lung ventilation. Prior work suggests that ventilation imaging has utility in all obstructive lung diseases. This is a Phase II clinical trial to assess HXe MRI capability of providing qualitative and quantitative clinical information regarding lung ventilation. Proton and xenon images will be acquired within single breath holds on 28 subjects per year, including healthy volunteers and patients with COPD and asthma. All studies will include repeat scans and Pulmonary Function Tests (PFT). Ventilation scans with Technetium-99m (Tc-99m) diethylene-triamine-pentaacetate (DTPA) aerosol scintigraphy will be acquired on lung patients. The primary goal of this aim is to validate the effectiveness of HXe ventilation MRI for delineating regions of normal and abnormal lung ventilation. To validate the regional depiction of ventilation, HXe MRI ventilation will be compared with nuclear medicine Tc-99m DTPA ventilation scintigraphy. The comparatively low spatial and temporal resolution of ventilation scintigraphy will limit this study to demonstrating only that HXe MRI ventilation is not inferior to the current clinical standard. Additionally, the concordance between measurements of the whole lung volume from both proton MRI and HXe MRI with PFT, the current clinical standard for lung volume measurement, will be assessed as a secondary outcome of the study.
Interventions
DRUGHXe MRI lung ventilation
MagniXene (HXe) is an Investigational New Drug made of xenon noble gas. Through a physical process using alkali vapors and powerful lasers, xenon atoms have their nuclear spin preferentially aligned (hyperpolarized), thus offering a highly enhanced signal inside an MRI scanner. High-resolution images of the lung spaces are acquired within a short breath-hold after inhalation of HXe.
Sponsors
University of Virginia
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Xemed LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
(healthy subjects): * Currently feeling well without respiratory symptoms. * No history of lung disease. * Never personally smoked (defined as less 100 cigarettes in their lifetime). Inclusion Criteria (COPD subjects): * Forced Expiratory Volume in 1 second (FEV1)\<80% predicted OR FEV1 to Forced Vital Capacity (FVC) ratio \<70% * Smoking history \>10 pack years * Subjects should be at their clinical baseline on the day of imaging * Subjects must be clinically stable in order to participate in the study Inclusion Criteria (asthma subjects): * Greater than 10% increase in FEV1 30-50 minutes after administration of albuterol; * Subjects should be at their clinical baseline on the day of imaging; * Subjects must be clinically stable in order to participate in the study.
Exclusion criteria
* Baseline oxygen requirement. * Blood oxygen saturation of 92% less than as measured by pulse oximetry on the day of imaging. * FEV1 percent predicted less than 25%. * Pregnancy or lactation. * Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded. * Chest circumference greater than that of the xenon MR coil. * History of congenital cardiac disease, chronic renal failure, or cirrhosis. * Inability to understand simple instructions or to hold still for approximately 10 seconds. * History of respiratory infection within 2 weeks prior to the MR scan. * History of heart attack, stroke and/or poorly controlled hypertension. * Known hypersensitivity to albuterol or any of its components, or levalbuterol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HXe MRI delineation of regions with abnormal lung ventilation in asthma and COPD patients | three years | Depiction of ventilation defects with HXe MRI is not worse than presently accepted clinical method, Tc-99m DTPA scintigraphy, as judged by skilled readers and software analysis. The primary outcome variable will be binary: if ventilation is detected the value is 1, the value is 0 otherwise (defect). The level of agreement between HXe MRI and Tc-99m DTPA will be statistically calculated. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ventilated volume of the lungs determined by HXe MRI | three years | A secondary outcome will be HXe MRI capability of describing parameters of the lung physiology, such as the ventilated volume of the lungs as compared to that extracted from imaging the pleural cavity via proton MRI for healthy subjects and from the pulmonary function tests for lung disease patients. |
| Number of ventilation defects in COPD and asthma patients | three years | The agreement between the number of ventilation defects as determined by skilled readers from HXe MRI and Tc-99m DTPA scintigraphy will be studied based on an extension of the Bland Altman statistical method for repeated measures data. |
Countries
United States
Outcome results
None listed